Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles

Area of Science:

• Nanotechnology
• Oncology
• Drug Delivery Systems

Background:

• Anticancer compounds often face challenges like normal tissue toxicity, poor specificity, and drug resistance.
• Solid lipid nanoparticles (SLN) present a viable strategy to mitigate these issues in cancer chemotherapy.
• Advancements in SLN, including hybrid nanoparticles and nanostructured lipid carriers, expand their therapeutic potential.

Purpose of the Study:

• To review the current applications of SLN for encapsulating and delivering cytotoxic anticancer agents.
• To discuss emerging trends in utilizing SLN for delivering chemosensitizers and other therapeutic molecules.
• To highlight the potential of SLN in improving cancer treatment efficacy and safety.

Main Methods:

• Literature review focusing on studies involving solid lipid nanoparticles in cancer therapy.
• Analysis of research on the encapsulation and delivery of cytotoxic compounds using SLN.
• Examination of recent advancements and future prospects of SLN in oncology.

Main Results:

• SLN effectively overcome common obstacles in anticancer drug delivery, including toxicity and drug resistance.
• Novel SLN formulations demonstrate enhanced capabilities for targeted cancer treatment.
• SLN show significant promise in delivering both cytotoxic agents and chemosensitizers.

Conclusions:

• Solid lipid nanoparticles represent a versatile and effective platform for improving cancer chemotherapy.
• Continued development of SLN is expected to lead to more efficient, specific, and safer anticancer drug delivery systems.
• SLN hold considerable potential to revolutionize cancer treatment strategies.